OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
• Abstract Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and
Gpcr
De novo design of GPCR exoframe modulators
• Abstract G-protein-coupled receptors (GPCRs) are important therapeutic targets and have been targeted mainly through their orthosteric site, where the endogenous agonist binds1.